Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome

Overview

The elderly represent a growing segment of the coronary population treated by dual antiplatelet therapy for percutaneous coronary intervention (PCI). These patients bear a higher risk of both ischemic events and bleeding complications than younger patients, with a subsequently higher rate of mortality.Recentprogress in antithrombotic treatment demonstrated the efficacy of adding a P2Y12 receptor antagonist to low-dose aspirin. Whether this benefit is also present in the elderly remains a debated issue due to the lack of specific data in this sub-population. The present study was realized to provide specific data on platelet response to clopidogrel, standard dose (75 mg) or prasugrel 5 mg in elderly patients (≥75 years old) whereas the superiority in PR response of the latter should allows the Prasugrel therapy in elderly patients with the better clinical efficacy and therapeutical safety already showed compared with Clopidogrel.

Full Title of Study: “PhaRmacodynamic Effect of Antiplatelet Agents in Elderly Patients: Standard Clopidogrel Versus prasugrEl Low Dose Therapy.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2013

Interventions

  • Drug: Clopidogrel
    • Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
  • Drug: Prasugrel
    • Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.

Arms, Groups and Cohorts

  • Experimental: Prasugrel low dose
    • Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
  • Experimental: Clopidogrel standard dose
    • Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.

Clinical Trial Outcome Measures

Primary Measures

  • superiority of prasugrel low dose
    • Time Frame: 30 days
    • The primary aim will be to investigate the antiplatelet effect of half dose of prasugrel (5 mg) versus standard dose of clopidogrel in patients with acute coronary syndrome and coronary diseases, treated with percutaneous coronary intervention and stent implantation.

Secondary Measures

  • Bleeding
    • Time Frame: 12 months
    • Bleeding (major, minor, or minimal according to the TIMI study criteria)
  • major adverse cardiac events
    • Time Frame: 12 months
    • major adverse cardiac events (cardiovascular death, myocardial infarction, and stroke) will be evaluated during the all period of treatment.

Participating in This Clinical Trial

Inclusion Criteria

  • Acute coronary syndrome – PCI with stent implantation – clopidogrel responsiveness – > 75 years of age. Exclusion Criteria:

  • history of bleeding diathesis – chronic oral anticoagulation treatment – contraindications to antiplatelet therapy – PCI or coronary artery bypass grafting (CABG) < 3 months – hemodynamic instability – platelet count < 100,000/μl – hematocrit < 30% – creatinine clearance < 25 ml/min – Patients with a history of stroke – other contraindication for prasugrel administration – patients weighing < 60 kg – high on treatment platelet reactivity

Gender Eligibility: All

Minimum Age: 75 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gennaro Sardella
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Gennaro Sardella, Associate Professor in Cardiology – University of Roma La Sapienza
  • Overall Contact(s)
    • Gennaro Sardella, MD, +390649979035, rino.sardella@uniroma1.it

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.